---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-042709"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2023-11-27T23:59:59+00:00"
generated_at: "2026-06-07T21:25:46.445442+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InspireMD announces EFS agreement with Jacobs Institute for CGuard EPS in tandem lesion stroke patients

## Summary
- Agreement with Jacobs Institute to execute an Early Feasibility Study (EFS) of CGuard EPS for acute stroke with tandem lesions.
- EFS to enroll 15 patients across 3 U.S. sites; no FDA-approved stents currently exist for this indication.
- CGuard EPS features MicroNet mesh covering for embolic protection, low metal surface area to reduce thrombotic risk.
- CEO Marvin Slosman states tandem lesion indication is a critical component of long-term growth strategy.
- Dr. Siddiqui notes ~20% of acute strokes are tandem, and stenting in conjunction with thrombectomy may be superior.

## SEC filing metadata
- accession: 0001493152-23-042709
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2023-11-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315223042709/0001493152-23-042709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315223042709/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-042709
- JSON: https://secwatch.observer/filing/0001493152-23-042709.json
- Plain text: https://secwatch.observer/filing/0001493152-23-042709.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.